Yd Bio Stock Performance
| YDES Stock | 11.33 0.05 0.44% |
On a scale of 0 to 100, YD Bio holds a performance score of 7. The firm owns a Beta (Systematic Risk) of 0.62, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, YD Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding YD Bio is expected to be smaller as well. Please check YD Bio's maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether YD Bio's current price history will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in YD Bio are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, YD Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.44 | Five Day Return 1.8 | Year To Date Return (5.58) | Ten Year Return (5.90) | All Time Return (5.90) |
1 | YD Bio Wins FDA 510 for Exovisse Lenses, OTC Path for Tears - Stock Titan | 11/24/2025 |
2 | YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN | 12/09/2025 |
3 | YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center | 12/16/2025 |
4 | YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap | 01/05/2026 |
5 | YDES is A Biotechnology Company on the Move | 01/07/2026 |
6 | YD Bio Regains Nasdaq Audit Committee Compliance After Board Committee Changes - TipRanks | 01/21/2026 |
7 | YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks | 01/30/2026 |
| Begin Period Cash Flow | 87.1 K | |
| Total Cashflows From Investing Activities | -2.9 M |
YD Bio Relative Risk vs. Return Landscape
If you would invest 884.00 in YD Bio on November 12, 2025 and sell it today you would earn a total of 249.00 from holding YD Bio or generate 28.17% return on investment over 90 days. YD Bio is currently generating 0.6314% in daily expected returns and assumes 6.6574% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than YDES, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
YD Bio Target Price Odds to finish over Current Price
The tendency of YDES Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 11.33 | 90 days | 11.33 | about 54.58 |
Based on a normal probability distribution, the odds of YD Bio to move above the current price in 90 days from now is about 54.58 (This YD Bio probability density function shows the probability of YDES Stock to fall within a particular range of prices over 90 days) .
YD Bio Price Density |
| Price |
Predictive Modules for YD Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as YD Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of YD Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
YD Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. YD Bio is not an exception. The market had few large corrections towards the YD Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold YD Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of YD Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.62 | |
σ | Overall volatility | 1.39 | |
Ir | Information ratio | 0.03 |
YD Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of YD Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for YD Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| YD Bio is way too risky over 90 days horizon | |
| YD Bio appears to be risky and price may revert if volatility continues | |
| YD Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 510.36 K. Net Loss for the year was (1.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| YD Bio generates negative cash flow from operations | |
| Latest headline from news.google.com: YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks |
YD Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of YDES Stock often depends not only on the future outlook of the current and potential YD Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. YD Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.1 M | |
| Cash And Short Term Investments | 3.1 M |
YD Bio Fundamentals Growth
YDES Stock prices reflect investors' perceptions of the future prospects and financial health of YD Bio, and YD Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on YDES Stock performance.
| Revenue | 510.36 K | ||||
| EBITDA | (1.28 M) | ||||
| Net Income | (1.41 M) | ||||
| Total Debt | 22.55 K | ||||
| Cash Flow From Operations | (1.84 M) | ||||
| Total Asset | 6.86 M | ||||
| Retained Earnings | (1.93 M) | ||||
| Working Capital | 3.2 M | ||||
About YD Bio Performance
Assessing YD Bio's fundamental ratios provides investors with valuable insights into YD Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the YD Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 44.14 | 41.94 | |
| Return On Tangible Assets | (0.39) | (0.37) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.24) | (0.22) | |
| Return On Equity | (0.19) | (0.18) |
Things to note about YD Bio performance evaluation
Checking the ongoing alerts about YD Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for YD Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| YD Bio is way too risky over 90 days horizon | |
| YD Bio appears to be risky and price may revert if volatility continues | |
| YD Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 510.36 K. Net Loss for the year was (1.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| YD Bio generates negative cash flow from operations | |
| Latest headline from news.google.com: YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks |
- Analyzing YD Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether YD Bio's stock is overvalued or undervalued compared to its peers.
- Examining YD Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating YD Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of YD Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of YD Bio's stock. These opinions can provide insight into YD Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for YDES Stock Analysis
When running YD Bio's price analysis, check to measure YD Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YD Bio is operating at the current time. Most of YD Bio's value examination focuses on studying past and present price action to predict the probability of YD Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YD Bio's price. Additionally, you may evaluate how the addition of YD Bio to your portfolios can decrease your overall portfolio volatility.